25 July 2018 - - Laguna Hills, California-based cellular therapies developer PharmaCyte Biotech, Inc. (OTCQB: PMCB) has successfully completed a study on the stability after "hand thawing" syringes of the Cell-in-a-Box encapsulated cells that will be used, in combination with low doses of the cancer prodrug ifosfamide, for the treatment of locally advanced, non-metastatic, inoperable pancreatic cancer (LAPC), the company said.
The results of the "hand thawing" study show that the viability of the cells remains essentially the same for at least 30 minutes at room temperature.
This serves to define the time that the interventional radiologist has to implant the Cell-in-a-Box capsules after thawing to ensure cellular viability within the patient.
At individual study sites, the frozen cells in the Cell-in-a-Box capsules within syringes will be hand-thawed and then kept at room temperature until they are implanted into a patient with LAPC.
The data obtained from this "hand thawing" study is required by the US Food and Drug Administration.
PharmaCyte Biotech is a clinical stage biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as "Cell-in-a-Box."
This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed.